Biocept
Biocept is a biotechnology company that provides innovative and highly-specialized services, technology, and tools for diagnosing and monitoring cancer. It focuses on developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests to provide cancer patients with personalized, actionable diagnostic information. Biocept's target audience includes oncologists, pathologists, clinical laboratories, and biopharma developers.
Biocept is committed to providing access to high-quality molecular testing technology and services to support personalized cancer therapy decisions. The company utilizes its proprietary Target Selector platform to capture and analyze rare cells from a variety of clinical specimens, such as blood and urine, for biomarkers that can be used to diagnose, classify, or monitor cancer. Some of their products and services include a comprehensive portfolio of molecular testing services, tests for various types of cancer, and liquid biopsy services to detect and monitor cancer.
Biocept's Target Selector platform stands out for its ability to capture and analyze rare cells from many clinical specimens in a highly sensitive and specific manner. Additionally, the platform offers a proprietary digital cancer diagnostics workflow for efficient and accurate results. This innovative technology differentiates Biocept from other companies in the field, and makes it a key player in the market.